LTR Medical is proud to announce that with TGA approval we will move to the next stage in launching the SAFIRA™ – SAFer Injection for Regional Anaesthesia in the Australian and New Zealand markets. Manufactured by Medovate, the SAFIRA™ gives Anaesthetists control over regional anaesthesia blocks by making it a single operator procedure. With an engineered safety solution to control injection pressure threshold, it reduces the change of nerve injury.
LTR Medical CEO Lee Rodne commented:
“The team at LTR Medical are excited to introduce the SAFIRA® to the Australian and New Zealand Markets. This groundbreaking new technology gives Anaesthetists greater control when placing nerve blocks and reduces the chance of nerve damage, improving patient outcomes.”
For further information, visit our product page or call us on 1800 319 419.